IHC Marker WT-1 is an immunohistochemistry test that detects Wilms Tumor 1 (WT1) protein expression in tissue cells. WT1 staining is used as a diagnostic marker in the evaluation and classification of certain tumors, particularly those of ovarian, endometrial, mesothelial, and kidney-related origin. The test is needed to help identify the likely tissue origin of a tumor and distinguish between morphologically similar cancers when interpreted with other pathology findings.
WT1 expression can occur in several tumor types, including many serous ovarian and endometrial carcinomas, mesothelial tumors, and Wilms tumors. Interpretation depends strongly on tumor morphology and clinical context.
Yes. WT1 is commonly included in immunohistochemical panels when evaluating certain ovarian tumors, particularly high-grade serous carcinoma, and can help support the suspected tumor origin.
It can provide useful evidence when combined with other markers and microscopic findings. WT1 alone is not sufficient to establish the diagnosis or site of origin.
WT1 can be expressed in mesothelial tumors and may be included in an immunohistochemical panel when mesothelioma is being considered. Other markers are usually evaluated alongside it.
No. Despite its name, WT1 expression is not limited to Wilms tumor. It can be found in several normal tissues and different tumor types.
A positive result indicates that WT1 protein expression was detected in the tested tissue. Its significance depends on the staining pattern, tumor morphology, and other immunohistochemical markers.
A negative result means WT1 expression was not detected at the assessed level. It may help exclude certain tumor possibilities but does not by itself rule out cancer.